CN
About Us
Portfolio
Meet the Founder
Our Big Moments
Our Strategy
mRNA
LNP
Newsroom
Press Release
Awards
Media Center
Join us
Contact Us
CN
About Us
Portfolio
Meet the Founder
Our Big Moments
Our Strategy
mRNA
LNP
Newsroom
Press Release
Awards
Media Center
Join us
Contact Us
Press Release
Newsroom
Press Release
Awards
Media Center
Press Release
INNORNA’s Covid mRNA Vaccine Approved by New Zealand for Phase I Clinical Trial
2022-12-20
Shenzhen, December 20, 2022—INNORNA announced that New Zealand Medicines and Medical Devices Safety Administration (MEDSAFE) approved a phase I clinical trial for its COVID-19 vaccine to conduct Head to Head comparative study against mRNA vaccines on the market in Europe and the United States.
Learn More +
InnoRNA and BeiGene Announce Strategic Research Collaboration to Jointly Discover Novel mRNA Therapies
2022-07-06
BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs
Learn More +
INNORNA raises USD 120 million in Series B funding
2022-03-28
Shenzhen, March 28, 2022 - Shenzhen INNORNA Biotechnology Co., Ltd. (hereinafter referred to as “INNORNA”) officially announced that it has raised USD 120 million in Series B funding. CDH Investment and HHF Capital were the lead-investors and E Fund Capital and Blue Ocean Capital Group were co-inv
Learn More +
INNORNA raises hundreds of millions RMB in Series A funding
2021-07-28
Shenzhen, July 28, 2021- Shenzhen INNORNA Biotechnology Co., Ltd. (hereinafter referred to as “INNORNA”) officially announced that it has raised hundreds of millions RMB in Series A funding in the first quarter of the year, leading in funding size among competitors in the same track and same serie
Learn More +
Home
Pre
Next
Last
Pre
Next